Aeterna Zentaris (AEZS) Stock Price, News & Analysis

Company Overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $4.08 to $4.30
• 50-Day Range: $3.79 to $6.50
• 52-Week Range: $3.96 to $12.00
• Volume: 2,443 shs
• Average Volume: 7,305 shs
• Market Capitalization: $7.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Buy

Aeterna Zentaris Stock Analysis - MarketRank™

Aeterna Zentaris scored higher than 28% of companies evaluated by MarketBeat, and ranked 844th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aeterna Zentaris has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aeterna Zentaris is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aeterna Zentaris is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aeterna Zentaris has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AEZS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aeterna Zentaris does not currently pay a dividend.

Dividend Growth

Aeterna Zentaris does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AEZS.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Aeterna Zentaris this week, compared to 0 articles on an average week.

MarketBeat Follows

2 people have added Aeterna Zentaris to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.10% of the stock of Aeterna Zentaris is held by insiders.

Percentage Held by Institutions

Only 0.73% of the stock of Aeterna Zentaris is held by institutions.

AEZS Stock Analysis - Frequently Asked Questions

How have AEZS shares performed this year?

Aeterna Zentaris' stock was trading at $7.44 on January 1st, 2024. Since then, AEZS shares have decreased by 44.3% and is now trading at $4.1450.
View the best growth stocks for 2024 here.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($2.00) by $1.00. The biopharmaceutical company earned $0.60 million during the quarter, compared to analyst estimates of $0.60 million. Aeterna Zentaris had a negative net margin of 760.32% and a negative trailing twelve-month return on equity of 83.45%.

When did Aeterna Zentaris' stock split?

Aeterna Zentaris's stock reverse split on the morning of Friday, May 3rd 2024. The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Who are Aeterna Zentaris' major shareholders?

Top institutional investors of Aeterna Zentaris include Concourse Financial Group Securities Inc..

How do I buy shares of Aeterna Zentaris?

Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aeterna Zentaris own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB) and ADMA Biologics (ADMA).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 9/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AEZS
• CUSIP: N/A
• CIK: 1113423
• Web: www.zentaris.com
• Phone: (418) 652-8525
• Fax: 418-948-9191
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.00
• High Stock Price Target: $60.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +1,347.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($14.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,550,000.00
• Net Margins: -760.32%
• Pretax Margin: -760.28%
• Return on Equity: -83.45%
• Return on Assets: -45.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.94
• Quick Ratio: 5.93

Sales & Book Value

• Annual Sales: $2.37 million
• Price / Sales: 3.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.99 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 1,793,000
• Free Float: 1,791,000
• Market Cap: $7.43 million
• Optionable: No Data
• Beta: 1.55